Depatuxizumab

Drug Profile

Depatuxizumab

Alternative Names: 806; 806 antibody; ABT-806; Anti-EGFR monoclonal antibody 806; Antibody 806; ch806; mAb 806

Latest Information Update: 23 Jan 2013

Price : $50

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer AbbVie
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 Jan 2013 ABT 806 is still in phase I trials for Solid tumours in USA and Australia
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 29 Feb 2012 Abbott initiates enrolment in a phase I trial for Solid tumours in Australia (NCT01406119)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top